Research methodologies to address clinical unmet needs and challenges in alcohol‐associated liver disease

Ashwani K. Singal, Paul Kwo, Allison Kwong, Suthat Liangpunsakul, Alexandre Louvet, Pranoti Mandrekar, Craig McClain, Jessica Mellinger, Gyongyi Szabo, Norah Terrault, Mark Thursz, Gerald S. Winder, W. Ray Kim, Vijay H. Shah – 7 September 2021 – Alcohol‐associated liver disease (ALD) is emerging worldwide as the leading cause of liver‐related morbidity, mortality, and indication for liver transplantation.

Magnetic resonance elastography plus Fibrosis‐4 versus FibroScan–aspartate aminotransferase in detection of candidates for pharmacological treatment of NASH‐related fibrosis

Nobuharu Tamaki, Kento Imajo, Suzanne Sharpton, Jinho Jung, Nobuyoshi Kawamura, Masato Yoneda, Mark A. Valasek, Cynthia Behling, Claude B. Sirlin, Atsushi Nakajima, Rohit Loomba – 7 September 2021

Alcohol‐Induced Liver Injury: Down‐regulation and Redistribution of Rab3D Results in Atypical Protein Trafficking

Carol A. Casey, Amanda J. Macke, Ryan R. Gough, Artem N. Pachikov, Mary E. Morris, Paul G. Thomes, Jacy L. Kubik, Melissa S. Holzapfel, Armen Petrosyan – 6 September 2021 – Previous work from our laboratories has identified multiple defects in endocytosis, protein trafficking, and secretion, along with altered Golgi function after alcohol administration.

Direct AMPK Activation Corrects NASH in Rodents Through Metabolic Effects and Direct Action on Inflammation and Fibrogenesis

Pascale Gluais‐Dagorn, Marc Foretz, Gregory R. Steinberg, Battsetseg Batchuluun, Anna Zawistowska‐Deniziak, Joost M. Lambooij, Bruno Guigas, David Carling, Pierre‐Axel Monternier, David E. Moller, Sebastien Bolze, Sophie Hallakou‐Bozec – 6 September 2021 – No approved therapies are available for nonalcoholic steatohepatitis (NASH). Adenosine monophosphate–activated protein kinase (AMPK) is a central regulator of cell metabolism; its activation has been suggested as a therapeutic approach to NASH.

Subscribe to